• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    Milestone Scientific Inc. filed SEC Form 8-K: Leadership Update, Other Events, Financial Statements and Exhibits

    8/5/25 5:15:35 PM ET
    $MLSS
    Industrial Specialties
    Health Care
    Get the next $MLSS alert in real time by email
    mlss20250804_8k.htm
    false 0000855683 0000855683 2025-07-31 2025-07-31
     
    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549
     
    FORM 8-K
     
    CURRENT REPORT
    Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
     
    Date of Report (Date of earliest event reported): July 31, 2025
     
    Milestone Scientific Inc.
    (Exact name of registrant as specified in its charter)
             
    Delaware
    (State or other jurisdiction
    of incorporation)
     
    001-14053
    (Commission
    File Number)
     
    13-3545623
    (IRS Employer
    Identification No.)
         
    425 Eagle Rock Avenue
    Suite 403
    Roseland, New Jersey
    (Address of principal executive offices)
     
    07068
    (Zip Code)
     
    Registrant’s telephone number, including area code (973) 535-2717
     
    (Former name or former address, if changed since last report.)
     
    Securities registered pursuant to Section 12(b) of the Act:
    Title of each class
    Trading Symbol(s)
    Name on exchange on which registered
    Common Stock
    MLSS
    NYSE American
     
    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instructions A.2. below):
     
    ☐
    Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
     
    ☐
    Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
     
    ☐
    Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
     
    ☐
    Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
     
     
    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
     
    Emerging growth company ☐
     
    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act ☐
     
     

     
     
    Item 5.02 —  Departure of directors or certain officers; election of directors; appointment of certain officers; compensatory arrangements of certain officers
     
    Effective July 31, 2025, the Board of Directors of Milestone Scientific Inc. (the “Company”) appointed Eric Hines as President and Chief Executive Officer, and as a director of the Company. From July 31, 2025 through December 31, 2025 (the “Initial Term”), Mr. Hines will be entitled to base compensation at the rate of $15,000 per month. From January 1, 2026, subject to Mr. Hines’s continued employment at the Company by mutual agreement (the “Extended Term”), Mr. Hines will be entitled to base compensation at the rate of $25,000 per month. In addition to his base compensation, Mr. Hines will be granted options (the “Signing Bonus Options”) for an aggregate of 2,000,000 shares of Common Stock of the Company.  The exercise price of the Signing Bonus Options will be the fair market value of shares of Common Stock of the Company on the date of grant. Ten percent (10%) of the Signing Bonus Options will vest on the date of grant and the remaining ninety percent (90%) will vest in three (3) equal annual installments of 600,000 shares each. In addition, it is expected that Mr. Hines would be entitled to receive an annual incentive bonus, comprised of (i) separate performance-based bonuses; and (ii) a discretionary bonus, each as determined by the Company’s Compensation Committee, in its sole discretion.
     
    Mr. Hines most recently served as President of North America at Ex Libris Group (September 2014 - June 2021), a global provider of cloud-based solutions for higher education and libraries. From June 2021 to July 2025, Mr. Hines was involved in providing consulting services for Alethea, a technology start-up company, and also invested in commercial and personal real estate ventures. Prior to his role at Ex Libris Group, Mr. Hines held various roles at NICE Systems (October 2004-June 2014), a multinational company that designs and manufactures smart home security and automation products. Mr. Hines served as Senior Director of Sales at NICE Systems from October 2004 to November 2005, and subsequently served as Vice President of several North American divisions of NICE Systems from November 2005 through June 2014. Prior thereto, Mr. Hines served as Regional Director of Sales at AMDOCS Clarify CRM (October 2003- October 2004),  a provider of customer relationship management (CRM) solutions to the communications industry.
     
    Mr. Hines received a BS in Chemistry from Wake Forest University in 1989 and an MBA in International Business from Xavier University in 1996.
     
    Item 8.01 - Other Events
     
    On August 1, 2025, the Company issued a press release announcing the appointment of Mr. Hines as Chief Executive Officer. The press release is attached hereto as Exhibit 99.1.
     
    Item 9.01 Financial Statements and Exhibits
     
    (d) Exhibits
     
    99.1       Press Release August 1, 2025
    104       Cover Page Interactive Data File (embedded within the Inline XBRL document)
     
     

     
     
    SIGNATURES
     
    Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
     
     
     
    MILESTONE SCIENTIFIC INC.
     
     
    Dated: August 5, 2025 
    By:  
    /s/ Neal Goldman  
       
    Neal Goldman 
     
       
    Interim Chief Executive Officer
     
     
     
    Get the next $MLSS alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $MLSS

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $MLSS
    SEC Filings

    View All

    Milestone Scientific Inc. filed SEC Form 8-K: Leadership Update, Other Events, Financial Statements and Exhibits

    8-K - MILESTONE SCIENTIFIC INC. (0000855683) (Filer)

    8/5/25 5:15:35 PM ET
    $MLSS
    Industrial Specialties
    Health Care

    Milestone Scientific Inc. filed SEC Form 8-K: Leadership Update, Regulation FD Disclosure

    8-K - MILESTONE SCIENTIFIC INC. (0000855683) (Filer)

    5/19/25 2:05:20 PM ET
    $MLSS
    Industrial Specialties
    Health Care

    SEC Form 10-Q filed by Milestone Scientific Inc.

    10-Q - MILESTONE SCIENTIFIC INC. (0000855683) (Filer)

    5/15/25 4:01:13 PM ET
    $MLSS
    Industrial Specialties
    Health Care

    $MLSS
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Milestone Scientific Achieves 25% Increase in Revenue for the Second Quarter of 2025

    ROSELAND, N.J., Aug. 14, 2025 (GLOBE NEWSWIRE) -- Milestone Scientific Inc. (NYSE:MLSS), a leading developer of computerized drug delivery instruments that provide painless and precise injections, today provides a business update and reported financial results for the second quarter ended June 30, 2025. Neal Goldman, Chairman of the Board, stated, "We are pleased with our revenue performance in the second quarter, delivering a 25% increase in revenue to $2.3 million, driven by strong international dental sales, which more than doubled year-over-year. We also maintained a strong gross margin of 70%, reflecting the benefits of our high-margin dental business and disciplined cost management.

    8/14/25 4:15:00 PM ET
    $MLSS
    Industrial Specialties
    Health Care

    Milestone Scientific Schedules Second Quarter 2025 Financial Results and Business Update Conference Call

    ROSELAND, N.J., Aug. 13, 2025 (GLOBE NEWSWIRE) -- Milestone Scientific Inc. (NYSE:MLSS), a leading developer of computerized drug delivery instruments, that provide painless and precise injections, today announced that it will host a conference call at 8:00 AM Eastern Time on Friday, August 15th, 2025, to discuss the company's financial results for the second quarter ended June 30, 2025, as well as the company's corporate progress and other developments. The conference call will be available via telephone by dialing toll free 888-506-0062 for U.S. callers or +1 973-528-0011 for international callers and by entering the access code: 470429. A webcast and replay of the call may be accessed

    8/13/25 11:45:00 AM ET
    $MLSS
    Industrial Specialties
    Health Care

    Milestone Scientific Appoints Jason Papes as Senior Vice President, Global Head of Sales and Marketing

    ROSELAND. N.J., Aug. 06, 2025 (GLOBE NEWSWIRE) -- Milestone Scientific Inc. (NYSE:MLSS), a leading developer of computerized drug delivery instruments that provide painless and precise injections, today announced the appointment of Jason Papes as Senior Vice President, Global Head of Sales and Marketing, effective immediately. Mr. Papes brings more than three decades of experience in sales, marketing, and business development within the healthcare industry, including leadership roles at large-cap medical technology companies and successful entrepreneurial ventures. His expertise spans orthopedics, neurology, pain management, and digital imaging, with a track record of building high-perfor

    8/6/25 8:30:00 AM ET
    $MLSS
    Industrial Specialties
    Health Care

    $MLSS
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Large owner Bp4 S.R.L. sold $6,400 worth of shares (10,000 units at $0.64), decreasing direct ownership by 0.11% to 9,298,724 units (SEC Form 4)

    4 - MILESTONE SCIENTIFIC INC. (0000855683) (Issuer)

    7/22/25 4:36:09 PM ET
    $MLSS
    Industrial Specialties
    Health Care

    Large owner Bp4 S.R.L. sold $62,798 worth of shares (92,900 units at $0.68), decreasing direct ownership by 0.99% to 9,308,799 units (SEC Form 4)

    4 - MILESTONE SCIENTIFIC INC. (0000855683) (Issuer)

    7/10/25 5:04:30 PM ET
    $MLSS
    Industrial Specialties
    Health Care

    Large owner Bp4 S.R.L. sold $21,882 worth of shares (27,882 units at $0.78), decreasing direct ownership by 0.30% to 9,417,608 units (SEC Form 4)

    4 - MILESTONE SCIENTIFIC INC. (0000855683) (Issuer)

    7/2/25 4:31:02 PM ET
    $MLSS
    Industrial Specialties
    Health Care

    $MLSS
    Leadership Updates

    Live Leadership Updates

    View All

    Milestone Scientific Appoints Jason Papes as Senior Vice President, Global Head of Sales and Marketing

    ROSELAND. N.J., Aug. 06, 2025 (GLOBE NEWSWIRE) -- Milestone Scientific Inc. (NYSE:MLSS), a leading developer of computerized drug delivery instruments that provide painless and precise injections, today announced the appointment of Jason Papes as Senior Vice President, Global Head of Sales and Marketing, effective immediately. Mr. Papes brings more than three decades of experience in sales, marketing, and business development within the healthcare industry, including leadership roles at large-cap medical technology companies and successful entrepreneurial ventures. His expertise spans orthopedics, neurology, pain management, and digital imaging, with a track record of building high-perfor

    8/6/25 8:30:00 AM ET
    $MLSS
    Industrial Specialties
    Health Care

    Milestone Scientific Appoints Eric C. Hines as Chief Executive Officer

    ROSELAND, N.J., Aug. 01, 2025 (GLOBE NEWSWIRE) -- Milestone Scientific Inc. (NYSE:MLSS), a leading developer of computerized drug delivery instruments that provide painless and precise injections, today announced the appointment of Eric C. Hines as Chief Executive Officer, effective immediately. Mr. Hines brings more than 25 years of leadership experience in scaling sales-driven enterprise software companies, serving customers across a range of industries, including healthcare. Most recently, he served as President of North America at Ex Libris, a division of Clarivate, where he led operations across the U.S., Canada, and Latin America and increased annual revenue from approximately $50 m

    8/1/25 8:30:00 AM ET
    $MLSS
    Industrial Specialties
    Health Care

    Milestone Scientific Appoints Highly Accomplished MedTech Executive Shanth Thiyagalingam to Board of Directors

    ROSELAND, N.J., May 19, 2025 (GLOBE NEWSWIRE) -- Milestone Scientific Inc. (NYSE:MLSS), a leading developer of computerized drug delivery instruments that provide painless and precise injections, today announced that Shanth Thiyagalingam, BMedSc, MMKTG, MBA, has joined its Board of Directors, effective May 14, 2025. Mr. Thiyagalingam brings more than 20 years of global leadership in commercial scaling, product innovation, and strategic execution across the medical device and pharmaceutical industries. Newly appointed board member Shanth Thiyagalingam This appointment further supports Milestone Scientific's strategy to drive adoption of its CompuFlo® Epidural System, broaden access unde

    5/19/25 10:00:00 AM ET
    $MLSS
    Industrial Specialties
    Health Care

    $MLSS
    Financials

    Live finance-specific insights

    View All

    Milestone Scientific Achieves 25% Increase in Revenue for the Second Quarter of 2025

    ROSELAND, N.J., Aug. 14, 2025 (GLOBE NEWSWIRE) -- Milestone Scientific Inc. (NYSE:MLSS), a leading developer of computerized drug delivery instruments that provide painless and precise injections, today provides a business update and reported financial results for the second quarter ended June 30, 2025. Neal Goldman, Chairman of the Board, stated, "We are pleased with our revenue performance in the second quarter, delivering a 25% increase in revenue to $2.3 million, driven by strong international dental sales, which more than doubled year-over-year. We also maintained a strong gross margin of 70%, reflecting the benefits of our high-margin dental business and disciplined cost management.

    8/14/25 4:15:00 PM ET
    $MLSS
    Industrial Specialties
    Health Care

    Milestone Scientific Schedules Second Quarter 2025 Financial Results and Business Update Conference Call

    ROSELAND, N.J., Aug. 13, 2025 (GLOBE NEWSWIRE) -- Milestone Scientific Inc. (NYSE:MLSS), a leading developer of computerized drug delivery instruments, that provide painless and precise injections, today announced that it will host a conference call at 8:00 AM Eastern Time on Friday, August 15th, 2025, to discuss the company's financial results for the second quarter ended June 30, 2025, as well as the company's corporate progress and other developments. The conference call will be available via telephone by dialing toll free 888-506-0062 for U.S. callers or +1 973-528-0011 for international callers and by entering the access code: 470429. A webcast and replay of the call may be accessed

    8/13/25 11:45:00 AM ET
    $MLSS
    Industrial Specialties
    Health Care

    Milestone Scientific Achieves 22% Increase in Revenue for the Third Quarter of 2024

    Reports 57% increase in international dental sales for the third quarter of 2024 Advances commercial rollout of CompuFlo® Epidural System across additional pain management clinics following Medicare price assignment in multiple U.S. states ROSELAND, N.J., Nov. 14, 2024 (GLOBE NEWSWIRE) -- Milestone Scientific Inc. (NYSE:MLSS), a leading developer of computerized drug delivery instruments that provide painless and precise injections, today reported financial results for the third quarter ended September 30, 2024. Arjan Haverhals, CEO of Milestone Scientific, commented, "We are pleased to report a 22% year-over-year increase in total revenue, reaching $2.5 million for t

    11/14/24 4:30:00 PM ET
    $MLSS
    Industrial Specialties
    Health Care